(Corrects headline to clarify operating profit neat estimates)

Overview

* Esperion Q2 2025 total revenue grows 12% yr/yr to $82.4

mln

* U.S. net product revenue rises 42% yr/yr to $40.3 mln

* Company achieves first quarter of operating income,

beating

analyst expectations

Outlook

* Esperion expects sustainable profitability starting in Q1

2026

* Company reiterates 2025 operating expenses of $215 mln to

$235

mln

* Esperion anticipates Japan market approval in H2 2025

* Company expects Canada market approval in Q4 2025

Result Drivers

* COMMERCIAL EXECUTION - Strong commercial execution and

growing

adoption of bempedoic acid therapies drove revenue growth, per

CEO Sheldon Koenig

* ANDA SETTLEMENTS - Reached agreements with three ANDA

filers to

delay generic versions of NEXLETOL until 2040

* OPERATING INCOME - Achieved first quarter of operating

income

from ongoing business, indicating progress towards sustainable

profitability by Q1 2026

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $40.27

Product mln

Sales

Q2 Net Beat -$4.79 -$27 mln

Income mln (5

Analysts

)

Q2 Beat $15.03 -$15.80

Operatin mln mln (4

g Income Analysts

)

Q2 Basic -$0.02

EPS

Q2 $67.36

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy"

and

the breakdown of recommendations is 5 "strong buy" or "buy", 2

"hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the

pharmaceuticals

peer group is "buy"

* Wall Street's median 12-month price target for Esperion

Therapeutics Inc ( ESPR ) is $4.00, about 62.7% above its August 4

closing price of $1.49

Press Release:

(This story was created using Reuters automation and AI based

on LSEG and company data. It was checked and edited by a Reuters

journalist prior to publication.)